on behalf of the CHANCE Investigators † Background--Treatment with the combination of clopidogrel and aspirin taken soon after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 90-day risk of stroke in a large trial in China, but the cost-effectiveness is unknown. This study sought to estimate the cost-effectiveness of the clopidogrel-aspirin regimen for acute TIA or minor stroke.
T he early (90-day) risk of recurrence of stroke and other vascular events following index transient ischemic attack (TIA) and minor ischemic stroke is very high, even in patients treated with aspirin, the current standard of care. [1] [2] [3] Treatment with the combination of clopidogrel and aspirin taken soon after a TIA or minor stroke was found to decrease the 90-day risk of stroke (hazard ratio 0.68, 95% CI 0.57 to 0.81, P<0.001) but did not increase the risk of hemorrhage compared with aspirin alone in the CHANCE stroke trial (Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events Trial). 4 Although the clopidogrelaspirin regimen is a reasonable early management for TIA and minor ischemic stroke, the extent of its adoption and use in clinical practice will depend-to some extent-on its economic practicality. However, the cost-effectiveness, which is very important for patients, clinicians, and policy-makers, has not been evaluated. In this analysis, we sought to determine the cost-effectiveness of adding clopidogrel to aspirin in patients with acute TIA or minor stroke.
Methods Model Overview
We adhered to the recommendations of the Panel on Costeffectiveness in Health and Medicine. 5 Markov models are generally used to estimate the long term costs and outcomes associated with a disease and a particular healthcare intervention, in which the disease is divided into distinct states and transits between these states over a discrete time period under assigned transitions probabilities. 6 A Markov model was developed ( Figure 1 ) to simulate the cost-effectiveness of two antiplatelet treatment strategies for high-risk patients with acute minor stroke or TIA:
(1) clopidogrel-aspirin strategy: a 300-mg loading dose of clopidogrel followed by 75 mg clopidogrel per day on days 2 to 90 plus aspirin 75 to 300 mg on day 1 followed by 75 mg/ day on days 2 to 21 or (2) aspirin-alone strategy: aspirin 75 to 300 mg on day 1 followed by 75 mg/day on days 2 to 90. The base-case was a cohort of 100 000 patients (33% female), with mean age of 63 years at the time of acute ischemic minor stroke or TIA, which is the sex distribution and mean age of the patients who were enrolled in the CHANCE trial (Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events Trial). Patients in the two treatment arms entered the model at the Markov health state of minor or no disability and transited to other health states (ischemic stroke or intracranial hemorrhage with minor or no disability, moderate disability, severe disability, myocardial infarction, extracranial hemorrhage, and dead) in the next cycle. Death (by stroke or other causes) was the only absorbing state after which the patient was excluded from the model. Total direct medical costs and quality-adjusted lifeyears (QALYs) gained with each alternative were estimated for each health state at 90 days from onset of TIA or minor stroke and then estimated annually for the remaining 30 years. This analysis was conducted from the perspective of healthcare payers. The study protocol was approved by the ethics committee of Beijing Tiantan Hospital. All participants or their legal proxies provided written informed consent.
Input Parameters
Model input parameters were drawn from the published literature and directly from the results of the CHANCE trial (Tables 1 and 2 ). The death rates and the distribution of functional outcomes of patients treated with clopidogrel- aspirin or aspirin alone in the first 90 days were based on results from the CHANCE trial, derived directly from the trial database. Major extracranial hemorrhage risk of the two treatment arms at 90 days were estimated by excluding intracranial hemorrhage from total hemorrhage defined by GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) criteria, because extracranial hemorrhage were not explicitly defined in CHANCE trial. We assumed all patients stopped the clopidogrel-aspirin regimen and used aspirin alone after 90 days since dual-antiplatelet therapy is not recommended for routine secondary stroke prevention 7, 8 and aspirin alone is more commonly used than clopidogrel alone in the longterm setting after TIA and minor stroke. 9, 10 In our model, myocardial infarction and major extracranial hemorrhages were considered temporary health states unless they resulted in death. These probabilities were derived from the literature. [15] [16] [17] For nonfatal myocardial infarction and nonfatal major extracranial hemorrhage, we further assumed that all patients entering these health states would have a short-term disutility of only 2 weeks for nonfatal major extracranial hemorrhage and 30 days for nonfatal myocardial infarction.
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Costs
All costs were total costs, including both out-of-pocket costs and reimbursement levels, and converted to 2011 Chinese Yuan Renminbi (CNY) by using the medical care component of consumer price index. 14 One-time hospitalization costs for major events and annual posthospitalization costs were based on CNSR and the China Health Statistics Yearbook 2012.
14 Additional costs of the 90-day clopidogrel-aspirin regimen were based on the retail price of clopidogrel (brand) and aspirin according to Beijing Municipal Commission of Development and Reform. 22 Indirect economic costs such as lost work productivity were not included in this analysis. All costs and utilities were discounted by 3% per year. 23 
Health States
In the model, patients could undergo transitions between four poststroke disability states based on the modified Rankin Scale (mRS): minor or no disability (mRS 0 to 2), moderate disability (mRS 3 to 4), severe disability (mRS 5), or death (mRS 6). 24 At the end of each annual cycle, patients could remain in their current health state, transition to a lower health state due to recurrent stroke, or die due to a recurrent stroke or a nonvascular cause (see Figure 1 ).
Outcome Assessment
Health outcomes were measured in QALYs by multiplying years of life by utility scores derived from the literature. Utility estimates for stroke survivors were based on published utility values stratified by mRS category. 18, 19, 23, 25 Economic costs were measured as the difference of health 
Sensitivity Analysis
One-way sensitivity analyses were performed to test the robustness of model results on all variables across plausible ranges determined a priori. Plausible ranges were obtained from the literature or by varying estimates up to 20% in each direction (Table 2) . To evaluate the impact of the uncertainty in all variables simultaneously, a probabilistic sensitivity analysis was performed using Monte Carlo simulation in Ersatz v1.3 (a bootstrap add-in for Microsoft Excel for Windows; EpiGear International Pty Ltd). Costs were varied after assuming a lognormal distribution. Probabilities and utilities were varied according to a beta distribution. The simulation was run 10 000 times to capture stability of the results. Uncertainty was represented on a scatter-plot and cost-effectiveness acceptability curve. 
Results
Base-Case Analysis
In the base-case scenario, for a 63-year-old patient with acute minor stroke or TIA, early 90-day clopidogrel-aspirin regimen would result in a lifetime gain of 0.037 QALY at an additional cost of CNY 1250 (US$ 192) (Table 3) .Therefore, the ICER of early 90-day clopidogrel-aspirin regimen would be approximately CNY 33 800 (US$ 5200) per QALY gained. Using the threshold of CNY 105 000 (39 GDP per capita of China in 2011, US$ 16 200) as the willingness-to-pay per QALY, early 90-day clopidogrel-aspirin regimen was more cost-effective in the base-case scenario.
Sensitivity Analysis
One-way sensitivity analyses indicated that the study results were robust. The tornado diagram in Figure 2 illustrates the effect of varying input parameters on the ICER. Overall, results
were most sensitive to additional cost of 90-day clopidogrel regimen and annual posthospitalization cost of disabling stroke (mRS 3 to 5). When additional cost of 90-day clopidogrel regimen was decreased to CNY 210 (based on the generic clopidogrel price in the United States), the ICER of clopidogrel-aspirin decreased to CNY À14 300/QALY, which represents a cost saving with improved health. When annual posthospitalization cost of disabling stroke was varied from CNY 14254.6 to CNY 3239.7, the dual-antiplatelet therapy's ICER increased from CNY 25 000/QALY to CNY 53 500/ QALY. The ICER was relatively insensitive to varying parameters of proportion of ICH in recurrent stroke, utility of major extracranial bleed, utility of myocardial infarction, and hospitalization cost of ICH.
Results of 10 000 iteration probabilistic sensitivity analysis are shown in Figure 3 . In 10.6% of simulation runs, the clopidogrel-aspirin therapy was less costly and more effective than aspirin-alone therapy. Clopidogrel-aspirin therapy was cost-effective in 95.7% of the simulations at a willingness-topay threshold of CNY 105 000 ( 
Discussion
Based largely on the results of the CHANCE trial, this costeffectiveness analysis demonstrates that a 90-day clopidogrel-aspirin regimen increases costs but improves quality of life. A patient on dual antiplatelet therapy gained an additional 0.037 QALY over a lifetime but at an additional of CNY 1250 (US$ 192), resulting in an ICER of CNY 33 800 (US$ 5200) per QALY. The robustness of our overall conclusion that 90-day clopidogrel-aspirin regimen is cost-effective is supported by the sensitivity analysis. The lifetime gain of 0.037 QALY (0.44 quality-adjusted months) for early 90-day clopidogrelaspirin regimen of TIA and minor stroke is comparable to that of most stroke treatments. For example, the lifetime QALY gain is 0.56 for tissue plasminogen activator treatment for acute ischemic stroke in the 3-hour time window, 27 0.17 for clopidogrel (ccompared with aspirin) for secondary prevention in stroke patients. 15 The gain of QALYs associated with early 90-day clopidogrel-aspirin regimen of TIA and minor stroke is relatively smaller than that of other treatments mainly because, unlike other analyses did, our analysis referred to nondisabling cerebrovascular events (TIA and minor stroke) other than stroke with high severity. Cost-effectiveness was sensitive to the additional cost of 90-day clopidogrel regimen and the annual posthospitalization cost of disabled stroke. When clopidogrel price was decreased to CNY 78 (US$ 12, the generic clopidogrel price in US) for a 1-month supply, the additional cost of 90-day clopidogrel regimen was decreased, and dual-antiplatelet therapy became cost saving. If the annual posthospitalization cost of disabling stroke was reduced to approximately one-third of the base-case level, cost saving from dual antiplatelet therapy was decreased, but the resultant ICER was still substantially lower than the willingness-to-pay threshold.
In current guidelines for the early management of patients with acute ischemic stroke published by both the cerebrovascular disease group of Chinese Medical Association and by the American Heart Association/American Stroke Association, clopidogrel and aspirin combination therapy is not recommended for patients with minor ischemic stroke and TIA. 28, 29 Aspirin monotherapy is the current standard of care in China. However, guidelines have not incorporated results of the CHANCE trial and patients with aspirin monotherapy still have 90-day stroke risk of 10% to 20% after minor ischemic stroke or TIA. [1] [2] [3] Our study suggested that clopidogrel-aspirin combination therapy is a cost-effective alternative over aspirin monotherapy when taken soon after a TIA or minor stroke.
Our study has limitations that should be considered when interpreting the results. First, the external generalizability of our findings may be affected as it is based on the efficacy findings from a single trial performed in China (the CHANCE trial), whose participants were restricted to Chinese patients. It is not known whether combination regimen will be shown to be similarly effective in other populations or settings. Additionally, we used a base-case cohort based on the CHANCE trial patient characteristics (mean age was 63 years and 33% were female), with a low proportion of female TIA patients. This was different from typical TIA population from population-based cohorts, and may result in different events rates and medical resource use. 30, 31 32 This may have been because many of the patients in CNSR and ChinaQUEST studies were from urban locations where costs are greater. Additionally, several surveys explored poor rehabilitation and decreased adherence to secondary prevention of ischemic stroke in China after discharge, 9, [33] [34] [35] [36] which may dramatically influence the annual posthospitalization costs but would do so similarly in both groups. We estimated annual posthospital costs from data of the real world registry of CNSR. Third, in the Markov model, we assumed future transitions of health status based on events related to stroke recurrence and total nonstroke death and functional status as a result of other cause were not considered in this model. Some studies have shown that disability status also affects survival, 37, 38 and this was not included in the present analysis. Fourth, we assumed that patients remaining alive after recurrent stroke events were reallocated equally among disability categories of equal and greater disability. Finally, this analysis was conducted from the perspective of healthcare payers. If a societal perspective was taken, indirect costs such as lost work productivity should be included and it may probably influence the results of the model. 5 These assumptions may deviate from the real world, but are unlikely to affect the overall results of our study because our findings were robust over reasonable variations in all model inputs. Our study reflects costs and event rates in China. Results may not be generalizable to other countries. For example, the monthly cost of clopidogrel (CNY 650, US$ 100) is substantially greater in China than in the United States, where generic clopidogrel is available for CNY 78 (US$ 12) for a month supply while the costs of hospitalization and posthospital care are much greater in the United States. Clopidogrel will be available as a generic in China in 2017. If generic is introduced, the price will come down dramatically and will likely be cost saving.
Conclusions
Early treatment with a 90-day clopidogrel-aspirin regimen for acute TIA or minor stroke is highly cost-effective in China setting. Although clopidogrel is generic, Plavix is brand in China. If Plavix were generic, treatment with clopidogrelaspirin would have been cost saving.
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